NCT07017751

Brief Summary

This study aims to determine the effect of online education structured according to Pender's Health Promotion Model on symptom burden, medication adherence, and nutritional behaviour in patients with heart failure. The sample size was calculated using the 'G. Power-3.1.9.2' programme at a 95% confidence level prior to data collection. Accordingly, the minimum sample size required for the independent sample t-test for the study was determined to be 44 (22 for each group) based on an alpha value of 0.05, an effect size of 1.128, and a theoretical power of 95%. Taking data losses into account, a total of 60 patients (30 for each group) were planned to be included in the sample. Data will be collected using the Heart Failure Symptom Status Scale, Medication Adherence and Prescription Printing Scale (İURYÖ-7), Heart Failure Nutrition Behaviour Scale. 1: Prior to providing education to patients, they will be informed about the purpose of the study, the data collection method, and the topics to be covered in the education. Patients who agree to participate in the study will be asked to sign an informed consent form. All patients in the experimental and control groups will be asked to complete the Heart Failure Nutrition Behaviour Scale (HFNBS), Heart Failure Symptom Status Scale (HFSSS), and Medication Adherence and Prescription Writing Scale (MAPWS-79) before receiving education. 2: The contact information of all patients in the experimental group will be collected. Training will be provided online at a time and date convenient for the patients. 3: Patients in the control group will receive a digital training booklet prepared by the researcher at the contact address they provide. 4: Participants will be contacted 2 weeks, 1 month, and 2 months after the initial education session to obtain feedback on post-education dietary behaviours, medication adherence, and symptoms. 5: Four to six weeks after the training is completed, the 'Nutritional Behaviour Scale in Heart Failure,' 'Heart Failure Symptom Status Scale,' and 'Medication Adherence and Prescription Writing Scale (İURYÖ-7)' will be completed online again. The same forms will also be completed online by patients in the control group 4-6 weeks later.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
Completed

Started Jul 2025

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

June 4, 2025

Completed
8 days until next milestone

First Posted

Study publicly available on registry

June 12, 2025

Completed
1 month until next milestone

Study Start

First participant enrolled

July 15, 2025

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 15, 2025

Completed
4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

December 30, 2025

Completed
Last Updated

June 13, 2025

Status Verified

June 1, 2025

Enrollment Period

2 months

First QC Date

June 4, 2025

Last Update Submit

June 11, 2025

Conditions

Keywords

Symptom BurdenMedication AdherenceNutritional Behaviourheart failure

Outcome Measures

Primary Outcomes (3)

  • Heart Failure Symptom Status Scale

    The scale addresses seven primary symptoms: dyspnoea, dyspnoea when lying supine, fatigue, chest pain, oedema, sleep problems, dizziness, and loss of balance.The total score that can be obtained from the scale ranges from 0 to 84. An increase in the score indicates a greater symptom burden.

    Baseline and after 6 months

  • Medication Adherence and Prescription Writing Scale

    The scale can also be used to determine medication adherence in individuals with low literacy levels. The scale consists of two subscales: the medication adherence subscale ranges from 4 to 16 points, and the prescription subscale ranges from 3 to 12 points. Item 7 is reverse-coded in the scale.The scale consists of 7 items, with the lowest possible score being 7 and the highest possible score being 28. As the score obtained from the scale decreases, medication adherence increases.

    Baseline and after 6 months

  • Heart Failure Nutrition Behaviour Scale

    The HFNBS consists of four subscales: healthy habits, salt restriction, sugar restriction, and prevention of retention, and comprises a total of 19 items. . A high total score on the scale indicates that individuals have adopted a diet consistent with the recommended dietary guidelines for heart failure; a low score indicates that individuals are not following these recommendations. The interpretation of the scores is as follows: * 19 ≤ score \<46: Patients are not following the guidelines and expert recommendations. * 46 ≤ score \<51: Patients are following the guidelines and expert recommendations to some extent. * 51 ≤ score \<55: Patients are following the guidelines and expert recommendations to a moderate extent. * 55 ≤ score ≤76: Patients are following the guidelines and expert recommendations to a high extent.

    Baseline and after 6 months

Study Arms (2)

Intervetion group

EXPERIMENTAL

The intervention group will consist of 30 people. The intervention group will receive 45 minutes online education structured according to Pender's Health Promotion Model on symptom burden, medication adherence, and nutritional behaviour in patients with heart failure. Two weeks, one month, and two months after the initial education, participants will be contacted to obtain feedback on their post-education dietary behaviours, medication compliance, and symptoms.

Other: Heart failure medication

Control group

NO INTERVENTION

The control group will consist of 30 people. All patients will be asked to complete the Heart Failure Symptom Status Scale, Medication Adherence and Prescription Writing Scale. Patients in the control group will not receive any training. The same forms will be filled out for the final test 3 months later. Patients who wish to will be given the training provided in the experimental group.

Interventions

intervention group will receive 45 minutes online education structured according to Pender's Health Promotion Model on symptom burden, medication adherence, and nutritional behaviour in patients with heart failure. Two weeks, one month, and two months after the initial education, participants will be contacted to obtain feedback on their post-education dietary behaviours, medication compliance, and symptoms.

Also known as: Heart Failure training
Intervetion group

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Volunteering to participate in the study.
  • Diagnosed with heart failure.
  • Not having cognitive dysfunction.
  • Access to the internet and the technical infrastructure to participate in online training.

You may not qualify if:

  • Having severe cognitive or psychological disorders,
  • Having difficulty communicating,
  • Being in the process of heart transplantation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Çanakkale Onsekiz Mart University, Faculty of Health Sciences

Merkez, Çanakkale, 17100, Turkey (Türkiye)

Location

MeSH Terms

Conditions

Heart DiseasesHeart FailureMedication Adherence

Condition Hierarchy (Ancestors)

Cardiovascular DiseasesPatient CompliancePatient Acceptance of Health CareTreatment Adherence and ComplianceHealth BehaviorBehavior

Study Officials

  • NAİLE ALANKAYA, Assoc. Prof

    Çanakkale Onsekiz Mart University, Faculty of Health Sciences

    STUDY DIRECTOR

Central Study Contacts

Naile Alankaya, Assoc.Prof

CONTACT

Ahmet E. Güngördü

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
PREVENTION
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Assoc. Prof.

Study Record Dates

First Submitted

June 4, 2025

First Posted

June 12, 2025

Study Start

July 15, 2025

Primary Completion

September 15, 2025

Study Completion

December 30, 2025

Last Updated

June 13, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will not share

Locations